Alrefimotide, Riletamotide, Tapderimotide

3 trials

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

2 Completed trials

3 Sponsors

10 Countries

Phase II/III

Phase II

Phase II/III: 1 Phase II: 2

Indications tested

Ovarian cancer 1 Pleural mesothelioma malignant 1

Sponsors using this IMP

Nordic Society Of Gynaecological Oncology Clinical Trial Unit 1 Oslo University Hospital HF 1 Vestre Viken HF 1

All trials

3 total

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent O… Pending

2024-516327-14-00 Phase II 9 countries Nordic Society Of Gynaecological Oncology Clinical Trial Unit
Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) Ended

2022-502604-67-00 Phase II/III 4 countries Oslo University Hospital Hf
Efficacy and safety of UV1 vaccination +/- standard of care as first line treatment of patients with non-small cell lung cancer Ended

2022-502437-25-00 Phase II 1 country Vestre Viken HF

Showing 1–3 of 3 trials

← All drugs A–Z